Health Care [ 11/12 ] | Pharmaceuticals [ 49/75 ]
NASDAQ | Common Stock
Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer.
The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.
It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers.
The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024.
Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 15, 24 | -0.19 Increased by +32.14% | -0.23 Increased by +17.39% |
| Mar 14, 24 | -0.19 Increased by +26.64% | -0.25 Increased by +24.00% |
| Nov 15, 23 | -0.23 Increased by +10.89% | -0.29 Increased by +20.69% |
| Aug 11, 23 | -0.20 Decreased by -3.90% | -0.31 Increased by +35.48% |
| May 16, 23 | -0.28 Decreased by -41.99% | -0.30 Increased by +6.67% |
| Mar 17, 23 | -0.26 Decreased by -43.81% | - |
| Nov 15, 22 | -0.26 Decreased by -19.44% | - |
| Aug 12, 22 | -0.19 Increased by +28.20% | - |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 57.00 K Increased by 0.00% | -123.14 M Decreased by -2.80 K% | Decreased by -216.04 K% Decreased by -2.80 K% |
| Mar 31, 24 | 56.00 K Increased by 0.00% | -4.98 M Increased by +13.71% | Decreased by -8.90 K% Increased by +13.71% |
| Dec 31, 23 | 56.00 K Increased by 0.00% | -4.18 M Increased by +22.80% | Decreased by -7.47 K% Increased by +22.80% |
| Sep 30, 23 | 57.00 K Increased by 0.00% | -4.74 M Increased by +12.21% | Decreased by -8.31 K% Increased by +12.21% |
| Jun 30, 23 | 57.00 K Increased by 0.00% | -4.25 M Decreased by -5.62% | Decreased by -7.46 K% Decreased by -5.62% |
| Mar 31, 23 | 56.00 K - | -5.78 M - | Decreased by -10.31 K% - |
| Dec 31, 22 | 56.00 K - | -5.42 M - | Decreased by -9.68 K% - |
| Sep 30, 22 | 57.00 K - | -5.40 M - | Decreased by -9.47 K% - |